Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)	1 Months Ended	3 Months Ended		6 Months Ended
	Jun. 30, 2022 USD ($) shares	Jun. 30, 2022 USD ($) shares	Jun. 30, 2021 USD ($) shares	Jun. 30, 2022 USD ($) Segment shares	Jun. 30, 2021 USD ($) shares	Dec. 31, 2021 USD ($)
Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Accumulated deficit	$ (135,775,000)	$ (135,775,000)		$ (135,775,000)		$ (114,130,000)
Cash and cash equivalents	78,900,000	78,900,000		78,900,000		90,765,000
Clinical Trials	1,314,000	1,314,000		1,314,000		$ 518,000
Grants receivable	$ 38,000	$ 38,000		$ 38,000
Number of operating segments | Segment				1
Weighted-average shares subject to repurchase | shares		0	8,000	0	11,000
Research and development		$ 8,761,000	$ 5,192,000	$ 15,740,000	$ 9,105,000
Common Stock | ATM Program
Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Common stock shares issued | shares				46,000,000.0
Number of shares sold | shares	2,721,316	2,721,316		2,721,316
Net proceeds from sale of shares	$ 3,900,000	$ 3,900,000		$ 3,900,000